文献速递新发突发、热带与寄生虫病

RTS,S/AS01E疫苗接种后抗环子孢子蛋白NANP重复序列与C端IgG应答的持续时间及保护关联

Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial.
PubMed 文献 · Lancet Infect Dis · 2026-04-21

该研究基于RTS,S/AS01E疟疾疫苗III期试验,在6个非洲国家5-17月龄儿童中评估抗环子孢子蛋白NANP重复序列、C端及全长IgG应答。发现C端IgG较NANP重复序列IgG下降更慢,加强针后C端IgG超过初免后峰值,且C端IgG维持水平与疟疾风险降低独立相关。

要点

  • C端IgG较NANP重复序列IgG下降更慢,加强针后C端IgG超初免峰值。
  • 加强针后IgG维持水平而非峰值与疟疾风险降低相关。

核心结论

  • 抗环子孢子蛋白C端IgG较NANP重复序列IgG更持久。
  • 抗体维持水平是RTS,S/AS01E疫苗效力的更强预测因素。

研究设计与样本

  • 观察性辅助免疫学研究,嵌套于RTS,S/AS01E III期试验(NCT00866619,2009-11)。
  • 纳入6个非洲国家5-17月龄儿童1292例,检测初免和加强接种前后5个时间点IgG。

主要发现

  • 加强针后IgG维持水平而非峰值与疟疾风险降低相关。

临床怎么用

  • 关注RTS,S/AS01E接种后抗体维持水平,尤其C端IgG,作为保护评估指标。
  • 加强针可提升C端IgG至超过初免峰值,支持加强免疫策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The RTS,S/AS01E malaria vaccine provides partial protection against Plasmodium falciparum, largely mediated by antibodies targeting the circumsporozoite protein. Correlates of protection remain incompletely defined and have focused mainly on peak IgG responses to the immunodominant NANP-repeats, with less known about antibody durability or responses to the C-terminus of circumsporozoite protein. METHODS: In this observational study, we evaluated IgG responses to NANP-repeat, C-terminus, and full-length circumsporozoite protein constructs at five timepoints before and after primary and booster vaccination, in children aged 5-17 months from six African countries enrolled in the RTS,S/AS01E phase 3 trial (NCT00866619, 2009-11). Antibody kinetics were analysed with linear regressions, and associations with clinical malaria risk over 1 year with Cox models. FINDINGS: Between May 25, 2009, to March 5, 2010, 1292 children were recruited and included for analysis in this study. IgG levels declined more slowly for C-terminus than for NANP-repeat over 17 months after primary vaccination (geometric mean fold change 0·099 [95% CI 0·089-0·110] vs 0·055 [0·048-0·062]; p<0·0001). The booster significantly enhanced C-terminal IgG, exceeding post-primary peak levels (geometric mean fold change 1·98 [95% CI 1·77-2·21]), whereas NANP-repeat responses were restored but remained below post-primary levels (geometric mean fold changes 0·57 [95% CI 0·51-0·63]). Higher circumsporozoite protein IgG levels correlated with reduced malaria risk, particularly during maintenance phases, with stronger associations for C-terminus, which remained independently protective after adjustment for NANP-repeat antibodies (hazard ratio 0·60, 95% CI 0·43-0·83; p=0·0021). After boosting, maintenance but not peak IgG levels correlated with reduced malaria risk. INTERPRETATION: IgG to circumsporozoite protein C-terminus are more durable than those to the NANP-repeats. Antibody maintenance emerges as a stronger predictor of RTS,S/AS01E vaccine efficacy than peak responses. FUNDING: USA National Institute of Allergy and Infectious Diseases, National Institutes of Health; PATH and Malaria Vaccine Initiative; Spanish Ministerio de Economía y Competitividad; Instituto de Salud Carlos III; CERCA programme; and Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement, Generalitat de Catalunya.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lara-Escandell M, Sánchez L, Macià D, et al. Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial. Lancet Infect Dis. 2026. PMID: 42030969. doi:10.1016/S1473-3099(26)00081-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。